Birth Of A Giant: A Timeline Of Teva And Allergan's Generics Business
Executive Summary
Graphical timeline tracks the deals that shaped the two firms from turn of the last century to the present day.
You may also be interested in...
Merck's Biosims Business: What's For Sale And Who Will Buy It?
Merck KGaA is getting out of biosimilars – a unit that CEO Stefan Oschmann called the company's now redundant back up plan – to instead focus on its growing oncology pipeline, which includes recently acquired pipeline candidates from Vertex Pharma.
Merck's Biosims Business: What's For Sale And Who Will Buy It?
Merck KGaA is getting out of biosimilars – a unit that CEO Stefan Oschmann called the company's now redundant back up plan – to instead focus on its growing oncology pipeline, which includes recently acquired pipeline candidates from Vertex Pharma.
Teva, Allergan Generics: FTC Worried About A Multitude Of Markets, Not A Behemoth
Record-setting divestment order driven by sheer number of products where firms competed, not size of company that would result from acquisition.